Global Viral Vector and Vaccine Market Growth 2026-2032
The global Viral Vector and Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Viral Vector and Vaccine Industry Forecast” looks at past sales and reviews total world Viral Vector and Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Viral Vector and Vaccine sales for 2026 through 2032. With Viral Vector and Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector and Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector and Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Viral Vector and Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector and Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector and Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector and Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector and Vaccine market by product type, application, key manufacturers and key regions and countries.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Viral Vector and Vaccine Industry Forecast” looks at past sales and reviews total world Viral Vector and Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Viral Vector and Vaccine sales for 2026 through 2032. With Viral Vector and Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector and Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Viral Vector and Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Viral Vector and Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector and Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector and Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector and Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector and Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Adenovirus
- Fowlpox Virus
- Attenuated Yellow Fever
- Vaccinia Virus Vectors
Segmentation by Application:
- Research Institutes
- Biopharmaceutical Companies
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- ABL
- Addgene
- Aldevron
- Boehringer Ingelheim International GmbH
- Brammer Bio
- Charles River Laboratories
- Creative-Biogene
- Fujifilm Corporation
- General Electric
- Waisman Biomanufacturing
- Novasep
- Pfizer
- Spark Therapeutics
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Viral Vector and Vaccine market?
- What factors are driving Viral Vector and Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Viral Vector and Vaccine market opportunities vary by end market size?
- How does Viral Vector and Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Viral Vector and Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Viral Vector and Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Viral Vector and Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Viral Vector and Vaccine Segment by Type
2.2.1 Adenovirus
2.2.2 Fowlpox Virus
2.2.3 Attenuated Yellow Fever
2.2.4 Vaccinia Virus Vectors
2.2.5 Viral Vector and Vaccine Sales by Type
2.2.5.1 Global Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Viral Vector and Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Viral Vector and Vaccine Sale Price by Type (2021-2026)
2.3 Viral Vector and Vaccine Segment by Application
2.3.1 Research Institutes
2.3.2 Biopharmaceutical Companies
2.3.3 Others
2.3.4 Viral Vector and Vaccine Sales by Application
2.3.4.1 Global Viral Vector and Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global Viral Vector and Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Viral Vector and Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Viral Vector and Vaccine Breakdown Data by Company
3.1.1 Global Viral Vector and Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Viral Vector and Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Viral Vector and Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Viral Vector and Vaccine Revenue by Company (2021-2026)
3.2.2 Global Viral Vector and Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Viral Vector and Vaccine Sale Price by Company
3.4 Key Manufacturers Viral Vector and Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Viral Vector and Vaccine Product Location Distribution
3.4.2 Players Viral Vector and Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VIRAL VECTOR AND VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Viral Vector and Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Viral Vector and Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Viral Vector and Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Viral Vector and Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Viral Vector and Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Viral Vector and Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Viral Vector and Vaccine Sales Growth
4.4 APAC Viral Vector and Vaccine Sales Growth
4.5 Europe Viral Vector and Vaccine Sales Growth
4.6 Middle East & Africa Viral Vector and Vaccine Sales Growth
5 AMERICAS
5.1 Americas Viral Vector and Vaccine Sales by Country
5.1.1 Americas Viral Vector and Vaccine Sales by Country (2021-2026)
5.1.2 Americas Viral Vector and Vaccine Revenue by Country (2021-2026)
5.2 Americas Viral Vector and Vaccine Sales by Type (2021-2026)
5.3 Americas Viral Vector and Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector and Vaccine Sales by Region
6.1.1 APAC Viral Vector and Vaccine Sales by Region (2021-2026)
6.1.2 APAC Viral Vector and Vaccine Revenue by Region (2021-2026)
6.2 APAC Viral Vector and Vaccine Sales by Type (2021-2026)
6.3 APAC Viral Vector and Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Viral Vector and Vaccine by Country
7.1.1 Europe Viral Vector and Vaccine Sales by Country (2021-2026)
7.1.2 Europe Viral Vector and Vaccine Revenue by Country (2021-2026)
7.2 Europe Viral Vector and Vaccine Sales by Type (2021-2026)
7.3 Europe Viral Vector and Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Viral Vector and Vaccine by Country
8.1.1 Middle East & Africa Viral Vector and Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Viral Vector and Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Viral Vector and Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Viral Vector and Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Viral Vector and Vaccine
10.3 Manufacturing Process Analysis of Viral Vector and Vaccine
10.4 Industry Chain Structure of Viral Vector and Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Viral Vector and Vaccine Distributors
11.3 Viral Vector and Vaccine Customer
12 WORLD FORECAST REVIEW FOR VIRAL VECTOR AND VACCINE BY GEOGRAPHIC REGION
12.1 Global Viral Vector and Vaccine Market Size Forecast by Region
12.1.1 Global Viral Vector and Vaccine Forecast by Region (2027-2032)
12.1.2 Global Viral Vector and Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Viral Vector and Vaccine Forecast by Type (2027-2032)
12.7 Global Viral Vector and Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ABL
13.1.1 ABL Company Information
13.1.2 ABL Viral Vector and Vaccine Product Portfolios and Specifications
13.1.3 ABL Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ABL Main Business Overview
13.1.5 ABL Latest Developments
13.2 Addgene
13.2.1 Addgene Company Information
13.2.2 Addgene Viral Vector and Vaccine Product Portfolios and Specifications
13.2.3 Addgene Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Addgene Main Business Overview
13.2.5 Addgene Latest Developments
13.3 Aldevron
13.3.1 Aldevron Company Information
13.3.2 Aldevron Viral Vector and Vaccine Product Portfolios and Specifications
13.3.3 Aldevron Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Aldevron Main Business Overview
13.3.5 Aldevron Latest Developments
13.4 Boehringer Ingelheim International GmbH
13.4.1 Boehringer Ingelheim International GmbH Company Information
13.4.2 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Boehringer Ingelheim International GmbH Main Business Overview
13.4.5 Boehringer Ingelheim International GmbH Latest Developments
13.5 Brammer Bio
13.5.1 Brammer Bio Company Information
13.5.2 Brammer Bio Viral Vector and Vaccine Product Portfolios and Specifications
13.5.3 Brammer Bio Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Brammer Bio Main Business Overview
13.5.5 Brammer Bio Latest Developments
13.6 Charles River Laboratories
13.6.1 Charles River Laboratories Company Information
13.6.2 Charles River Laboratories Viral Vector and Vaccine Product Portfolios and Specifications
13.6.3 Charles River Laboratories Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Charles River Laboratories Main Business Overview
13.6.5 Charles River Laboratories Latest Developments
13.7 Creative-Biogene
13.7.1 Creative-Biogene Company Information
13.7.2 Creative-Biogene Viral Vector and Vaccine Product Portfolios and Specifications
13.7.3 Creative-Biogene Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Creative-Biogene Main Business Overview
13.7.5 Creative-Biogene Latest Developments
13.8 Fujifilm Corporation
13.8.1 Fujifilm Corporation Company Information
13.8.2 Fujifilm Corporation Viral Vector and Vaccine Product Portfolios and Specifications
13.8.3 Fujifilm Corporation Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Fujifilm Corporation Main Business Overview
13.8.5 Fujifilm Corporation Latest Developments
13.9 General Electric
13.9.1 General Electric Company Information
13.9.2 General Electric Viral Vector and Vaccine Product Portfolios and Specifications
13.9.3 General Electric Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 General Electric Main Business Overview
13.9.5 General Electric Latest Developments
13.10 Waisman Biomanufacturing
13.10.1 Waisman Biomanufacturing Company Information
13.10.2 Waisman Biomanufacturing Viral Vector and Vaccine Product Portfolios and Specifications
13.10.3 Waisman Biomanufacturing Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Waisman Biomanufacturing Main Business Overview
13.10.5 Waisman Biomanufacturing Latest Developments
13.11 Novasep
13.11.1 Novasep Company Information
13.11.2 Novasep Viral Vector and Vaccine Product Portfolios and Specifications
13.11.3 Novasep Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Novasep Main Business Overview
13.11.5 Novasep Latest Developments
13.12 Pfizer
13.12.1 Pfizer Company Information
13.12.2 Pfizer Viral Vector and Vaccine Product Portfolios and Specifications
13.12.3 Pfizer Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Pfizer Main Business Overview
13.12.5 Pfizer Latest Developments
13.13 Spark Therapeutics
13.13.1 Spark Therapeutics Company Information
13.13.2 Spark Therapeutics Viral Vector and Vaccine Product Portfolios and Specifications
13.13.3 Spark Therapeutics Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Spark Therapeutics Main Business Overview
13.13.5 Spark Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Viral Vector and Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Viral Vector and Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Viral Vector and Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Viral Vector and Vaccine Segment by Type
2.2.1 Adenovirus
2.2.2 Fowlpox Virus
2.2.3 Attenuated Yellow Fever
2.2.4 Vaccinia Virus Vectors
2.2.5 Viral Vector and Vaccine Sales by Type
2.2.5.1 Global Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Viral Vector and Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Viral Vector and Vaccine Sale Price by Type (2021-2026)
2.3 Viral Vector and Vaccine Segment by Application
2.3.1 Research Institutes
2.3.2 Biopharmaceutical Companies
2.3.3 Others
2.3.4 Viral Vector and Vaccine Sales by Application
2.3.4.1 Global Viral Vector and Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global Viral Vector and Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Viral Vector and Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Viral Vector and Vaccine Breakdown Data by Company
3.1.1 Global Viral Vector and Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Viral Vector and Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Viral Vector and Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Viral Vector and Vaccine Revenue by Company (2021-2026)
3.2.2 Global Viral Vector and Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Viral Vector and Vaccine Sale Price by Company
3.4 Key Manufacturers Viral Vector and Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Viral Vector and Vaccine Product Location Distribution
3.4.2 Players Viral Vector and Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VIRAL VECTOR AND VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Viral Vector and Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Viral Vector and Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Viral Vector and Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Viral Vector and Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Viral Vector and Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Viral Vector and Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Viral Vector and Vaccine Sales Growth
4.4 APAC Viral Vector and Vaccine Sales Growth
4.5 Europe Viral Vector and Vaccine Sales Growth
4.6 Middle East & Africa Viral Vector and Vaccine Sales Growth
5 AMERICAS
5.1 Americas Viral Vector and Vaccine Sales by Country
5.1.1 Americas Viral Vector and Vaccine Sales by Country (2021-2026)
5.1.2 Americas Viral Vector and Vaccine Revenue by Country (2021-2026)
5.2 Americas Viral Vector and Vaccine Sales by Type (2021-2026)
5.3 Americas Viral Vector and Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Viral Vector and Vaccine Sales by Region
6.1.1 APAC Viral Vector and Vaccine Sales by Region (2021-2026)
6.1.2 APAC Viral Vector and Vaccine Revenue by Region (2021-2026)
6.2 APAC Viral Vector and Vaccine Sales by Type (2021-2026)
6.3 APAC Viral Vector and Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Viral Vector and Vaccine by Country
7.1.1 Europe Viral Vector and Vaccine Sales by Country (2021-2026)
7.1.2 Europe Viral Vector and Vaccine Revenue by Country (2021-2026)
7.2 Europe Viral Vector and Vaccine Sales by Type (2021-2026)
7.3 Europe Viral Vector and Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Viral Vector and Vaccine by Country
8.1.1 Middle East & Africa Viral Vector and Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Viral Vector and Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Viral Vector and Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Viral Vector and Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Viral Vector and Vaccine
10.3 Manufacturing Process Analysis of Viral Vector and Vaccine
10.4 Industry Chain Structure of Viral Vector and Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Viral Vector and Vaccine Distributors
11.3 Viral Vector and Vaccine Customer
12 WORLD FORECAST REVIEW FOR VIRAL VECTOR AND VACCINE BY GEOGRAPHIC REGION
12.1 Global Viral Vector and Vaccine Market Size Forecast by Region
12.1.1 Global Viral Vector and Vaccine Forecast by Region (2027-2032)
12.1.2 Global Viral Vector and Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Viral Vector and Vaccine Forecast by Type (2027-2032)
12.7 Global Viral Vector and Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 ABL
13.1.1 ABL Company Information
13.1.2 ABL Viral Vector and Vaccine Product Portfolios and Specifications
13.1.3 ABL Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 ABL Main Business Overview
13.1.5 ABL Latest Developments
13.2 Addgene
13.2.1 Addgene Company Information
13.2.2 Addgene Viral Vector and Vaccine Product Portfolios and Specifications
13.2.3 Addgene Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Addgene Main Business Overview
13.2.5 Addgene Latest Developments
13.3 Aldevron
13.3.1 Aldevron Company Information
13.3.2 Aldevron Viral Vector and Vaccine Product Portfolios and Specifications
13.3.3 Aldevron Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Aldevron Main Business Overview
13.3.5 Aldevron Latest Developments
13.4 Boehringer Ingelheim International GmbH
13.4.1 Boehringer Ingelheim International GmbH Company Information
13.4.2 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim International GmbH Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Boehringer Ingelheim International GmbH Main Business Overview
13.4.5 Boehringer Ingelheim International GmbH Latest Developments
13.5 Brammer Bio
13.5.1 Brammer Bio Company Information
13.5.2 Brammer Bio Viral Vector and Vaccine Product Portfolios and Specifications
13.5.3 Brammer Bio Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Brammer Bio Main Business Overview
13.5.5 Brammer Bio Latest Developments
13.6 Charles River Laboratories
13.6.1 Charles River Laboratories Company Information
13.6.2 Charles River Laboratories Viral Vector and Vaccine Product Portfolios and Specifications
13.6.3 Charles River Laboratories Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Charles River Laboratories Main Business Overview
13.6.5 Charles River Laboratories Latest Developments
13.7 Creative-Biogene
13.7.1 Creative-Biogene Company Information
13.7.2 Creative-Biogene Viral Vector and Vaccine Product Portfolios and Specifications
13.7.3 Creative-Biogene Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Creative-Biogene Main Business Overview
13.7.5 Creative-Biogene Latest Developments
13.8 Fujifilm Corporation
13.8.1 Fujifilm Corporation Company Information
13.8.2 Fujifilm Corporation Viral Vector and Vaccine Product Portfolios and Specifications
13.8.3 Fujifilm Corporation Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Fujifilm Corporation Main Business Overview
13.8.5 Fujifilm Corporation Latest Developments
13.9 General Electric
13.9.1 General Electric Company Information
13.9.2 General Electric Viral Vector and Vaccine Product Portfolios and Specifications
13.9.3 General Electric Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 General Electric Main Business Overview
13.9.5 General Electric Latest Developments
13.10 Waisman Biomanufacturing
13.10.1 Waisman Biomanufacturing Company Information
13.10.2 Waisman Biomanufacturing Viral Vector and Vaccine Product Portfolios and Specifications
13.10.3 Waisman Biomanufacturing Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Waisman Biomanufacturing Main Business Overview
13.10.5 Waisman Biomanufacturing Latest Developments
13.11 Novasep
13.11.1 Novasep Company Information
13.11.2 Novasep Viral Vector and Vaccine Product Portfolios and Specifications
13.11.3 Novasep Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Novasep Main Business Overview
13.11.5 Novasep Latest Developments
13.12 Pfizer
13.12.1 Pfizer Company Information
13.12.2 Pfizer Viral Vector and Vaccine Product Portfolios and Specifications
13.12.3 Pfizer Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Pfizer Main Business Overview
13.12.5 Pfizer Latest Developments
13.13 Spark Therapeutics
13.13.1 Spark Therapeutics Company Information
13.13.2 Spark Therapeutics Viral Vector and Vaccine Product Portfolios and Specifications
13.13.3 Spark Therapeutics Viral Vector and Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Spark Therapeutics Main Business Overview
13.13.5 Spark Therapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Viral Vector and Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Viral Vector and Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Adenovirus
Table 4. Major Players of Fowlpox Virus
Table 5. Major Players of Attenuated Yellow Fever
Table 6. Major Players of Vaccinia Virus Vectors
Table 7. Global Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Viral Vector and Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Viral Vector and Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Viral Vector and Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Viral Vector and Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global Viral Vector and Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Viral Vector and Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Viral Vector and Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Viral Vector and Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Viral Vector and Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global Viral Vector and Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Viral Vector and Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Viral Vector and Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Viral Vector and Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Viral Vector and Vaccine Producing Area Distribution and Sales Area
Table 23. Players Viral Vector and Vaccine Products Offered
Table 24. Viral Vector and Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Viral Vector and Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Viral Vector and Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Viral Vector and Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Viral Vector and Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Viral Vector and Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Viral Vector and Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Viral Vector and Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Viral Vector and Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Viral Vector and Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas Viral Vector and Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Viral Vector and Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC Viral Vector and Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC Viral Vector and Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Viral Vector and Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe Viral Vector and Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe Viral Vector and Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Viral Vector and Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Viral Vector and Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Viral Vector and Vaccine
Table 54. Key Market Challenges & Risks of Viral Vector and Vaccine
Table 55. Key Industry Trends of Viral Vector and Vaccine
Table 56. Viral Vector and Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Viral Vector and Vaccine Distributors List
Table 59. Viral Vector and Vaccine Customer List
Table 60. Global Viral Vector and Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Viral Vector and Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Viral Vector and Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Viral Vector and Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Viral Vector and Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Viral Vector and Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Viral Vector and Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Viral Vector and Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Viral Vector and Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Viral Vector and Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Viral Vector and Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Viral Vector and Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Viral Vector and Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Viral Vector and Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. ABL Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. ABL Viral Vector and Vaccine Product Portfolios and Specifications
Table 76. ABL Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. ABL Main Business
Table 78. ABL Latest Developments
Table 79. Addgene Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Addgene Viral Vector and Vaccine Product Portfolios and Specifications
Table 81. Addgene Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Addgene Main Business
Table 83. Addgene Latest Developments
Table 84. Aldevron Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Aldevron Viral Vector and Vaccine Product Portfolios and Specifications
Table 86. Aldevron Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Aldevron Main Business
Table 88. Aldevron Latest Developments
Table 89. Boehringer Ingelheim International GmbH Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Boehringer Ingelheim International GmbH Viral Vector and Vaccine Product Portfolios and Specifications
Table 91. Boehringer Ingelheim International GmbH Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Boehringer Ingelheim International GmbH Main Business
Table 93. Boehringer Ingelheim International GmbH Latest Developments
Table 94. Brammer Bio Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Brammer Bio Viral Vector and Vaccine Product Portfolios and Specifications
Table 96. Brammer Bio Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Brammer Bio Main Business
Table 98. Brammer Bio Latest Developments
Table 99. Charles River Laboratories Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Charles River Laboratories Viral Vector and Vaccine Product Portfolios and Specifications
Table 101. Charles River Laboratories Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Charles River Laboratories Main Business
Table 103. Charles River Laboratories Latest Developments
Table 104. Creative-Biogene Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Creative-Biogene Viral Vector and Vaccine Product Portfolios and Specifications
Table 106. Creative-Biogene Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Creative-Biogene Main Business
Table 108. Creative-Biogene Latest Developments
Table 109. Fujifilm Corporation Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Fujifilm Corporation Viral Vector and Vaccine Product Portfolios and Specifications
Table 111. Fujifilm Corporation Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Fujifilm Corporation Main Business
Table 113. Fujifilm Corporation Latest Developments
Table 114. General Electric Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. General Electric Viral Vector and Vaccine Product Portfolios and Specifications
Table 116. General Electric Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. General Electric Main Business
Table 118. General Electric Latest Developments
Table 119. Waisman Biomanufacturing Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Waisman Biomanufacturing Viral Vector and Vaccine Product Portfolios and Specifications
Table 121. Waisman Biomanufacturing Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Waisman Biomanufacturing Main Business
Table 123. Waisman Biomanufacturing Latest Developments
Table 124. Novasep Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Novasep Viral Vector and Vaccine Product Portfolios and Specifications
Table 126. Novasep Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Novasep Main Business
Table 128. Novasep Latest Developments
Table 129. Pfizer Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Pfizer Viral Vector and Vaccine Product Portfolios and Specifications
Table 131. Pfizer Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Pfizer Main Business
Table 133. Pfizer Latest Developments
Table 134. Spark Therapeutics Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Spark Therapeutics Viral Vector and Vaccine Product Portfolios and Specifications
Table 136. Spark Therapeutics Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Spark Therapeutics Main Business
Table 138. Spark Therapeutics Latest Developments
Table 1. Viral Vector and Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Viral Vector and Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Adenovirus
Table 4. Major Players of Fowlpox Virus
Table 5. Major Players of Attenuated Yellow Fever
Table 6. Major Players of Vaccinia Virus Vectors
Table 7. Global Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Viral Vector and Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Viral Vector and Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Viral Vector and Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Viral Vector and Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global Viral Vector and Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Viral Vector and Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Viral Vector and Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Viral Vector and Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Viral Vector and Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global Viral Vector and Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Viral Vector and Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Viral Vector and Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Viral Vector and Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Viral Vector and Vaccine Producing Area Distribution and Sales Area
Table 23. Players Viral Vector and Vaccine Products Offered
Table 24. Viral Vector and Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Viral Vector and Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Viral Vector and Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Viral Vector and Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Viral Vector and Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Viral Vector and Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Viral Vector and Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Viral Vector and Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Viral Vector and Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Viral Vector and Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas Viral Vector and Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Viral Vector and Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC Viral Vector and Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC Viral Vector and Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Viral Vector and Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe Viral Vector and Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe Viral Vector and Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Viral Vector and Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Viral Vector and Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Viral Vector and Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Viral Vector and Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Viral Vector and Vaccine
Table 54. Key Market Challenges & Risks of Viral Vector and Vaccine
Table 55. Key Industry Trends of Viral Vector and Vaccine
Table 56. Viral Vector and Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Viral Vector and Vaccine Distributors List
Table 59. Viral Vector and Vaccine Customer List
Table 60. Global Viral Vector and Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Viral Vector and Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Viral Vector and Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Viral Vector and Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Viral Vector and Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Viral Vector and Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Viral Vector and Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Viral Vector and Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Viral Vector and Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Viral Vector and Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Viral Vector and Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Viral Vector and Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Viral Vector and Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Viral Vector and Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. ABL Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. ABL Viral Vector and Vaccine Product Portfolios and Specifications
Table 76. ABL Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. ABL Main Business
Table 78. ABL Latest Developments
Table 79. Addgene Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Addgene Viral Vector and Vaccine Product Portfolios and Specifications
Table 81. Addgene Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Addgene Main Business
Table 83. Addgene Latest Developments
Table 84. Aldevron Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Aldevron Viral Vector and Vaccine Product Portfolios and Specifications
Table 86. Aldevron Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Aldevron Main Business
Table 88. Aldevron Latest Developments
Table 89. Boehringer Ingelheim International GmbH Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Boehringer Ingelheim International GmbH Viral Vector and Vaccine Product Portfolios and Specifications
Table 91. Boehringer Ingelheim International GmbH Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Boehringer Ingelheim International GmbH Main Business
Table 93. Boehringer Ingelheim International GmbH Latest Developments
Table 94. Brammer Bio Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Brammer Bio Viral Vector and Vaccine Product Portfolios and Specifications
Table 96. Brammer Bio Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Brammer Bio Main Business
Table 98. Brammer Bio Latest Developments
Table 99. Charles River Laboratories Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Charles River Laboratories Viral Vector and Vaccine Product Portfolios and Specifications
Table 101. Charles River Laboratories Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Charles River Laboratories Main Business
Table 103. Charles River Laboratories Latest Developments
Table 104. Creative-Biogene Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Creative-Biogene Viral Vector and Vaccine Product Portfolios and Specifications
Table 106. Creative-Biogene Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Creative-Biogene Main Business
Table 108. Creative-Biogene Latest Developments
Table 109. Fujifilm Corporation Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Fujifilm Corporation Viral Vector and Vaccine Product Portfolios and Specifications
Table 111. Fujifilm Corporation Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Fujifilm Corporation Main Business
Table 113. Fujifilm Corporation Latest Developments
Table 114. General Electric Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. General Electric Viral Vector and Vaccine Product Portfolios and Specifications
Table 116. General Electric Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. General Electric Main Business
Table 118. General Electric Latest Developments
Table 119. Waisman Biomanufacturing Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Waisman Biomanufacturing Viral Vector and Vaccine Product Portfolios and Specifications
Table 121. Waisman Biomanufacturing Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Waisman Biomanufacturing Main Business
Table 123. Waisman Biomanufacturing Latest Developments
Table 124. Novasep Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Novasep Viral Vector and Vaccine Product Portfolios and Specifications
Table 126. Novasep Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Novasep Main Business
Table 128. Novasep Latest Developments
Table 129. Pfizer Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Pfizer Viral Vector and Vaccine Product Portfolios and Specifications
Table 131. Pfizer Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Pfizer Main Business
Table 133. Pfizer Latest Developments
Table 134. Spark Therapeutics Basic Information, Viral Vector and Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Spark Therapeutics Viral Vector and Vaccine Product Portfolios and Specifications
Table 136. Spark Therapeutics Viral Vector and Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Spark Therapeutics Main Business
Table 138. Spark Therapeutics Latest Developments
LIST OF FIGURES
Figure 1. Picture of Viral Vector and Vaccine
Figure 2. Viral Vector and Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Viral Vector and Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Viral Vector and Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Viral Vector and Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Viral Vector and Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Viral Vector and Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Adenovirus
Figure 12. Product Picture of Fowlpox Virus
Figure 13. Product Picture of Attenuated Yellow Fever
Figure 14. Product Picture of Vaccinia Virus Vectors
Figure 15. Global Viral Vector and Vaccine Sales Market Share by Type in 2026
Figure 16. Global Viral Vector and Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Viral Vector and Vaccine Consumed in Research Institutes
Figure 18. Global Viral Vector and Vaccine Market: Research Institutes (2021-2026) & (K Units)
Figure 19. Viral Vector and Vaccine Consumed in Biopharmaceutical Companies
Figure 20. Global Viral Vector and Vaccine Market: Biopharmaceutical Companies (2021-2026) & (K Units)
Figure 21. Viral Vector and Vaccine Consumed in Others
Figure 22. Global Viral Vector and Vaccine Market: Others (2021-2026) & (K Units)
Figure 23. Global Viral Vector and Vaccine Sale Market Share by Application (2025)
Figure 24. Global Viral Vector and Vaccine Revenue Market Share by Application in 2026
Figure 25. Viral Vector and Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global Viral Vector and Vaccine Sales Market Share by Company in 2026
Figure 27. Viral Vector and Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global Viral Vector and Vaccine Revenue Market Share by Company in 2026
Figure 29. Global Viral Vector and Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Viral Vector and Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas Viral Vector and Vaccine Sales Market Share by Country in 2026
Figure 40. Americas Viral Vector and Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Viral Vector and Vaccine Sales Market Share by Region in 2026
Figure 48. APAC Viral Vector and Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Viral Vector and Vaccine Sales Market Share by Country in 2026
Figure 59. Europe Viral Vector and Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Viral Vector and Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Viral Vector and Vaccine in 2026
Figure 76. Manufacturing Process Analysis of Viral Vector and Vaccine
Figure 77. Industry Chain Structure of Viral Vector and Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Viral Vector and Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global Viral Vector and Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Viral Vector and Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Viral Vector and Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Viral Vector and Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Viral Vector and Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Viral Vector and Vaccine
Figure 2. Viral Vector and Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Viral Vector and Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Viral Vector and Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Viral Vector and Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Viral Vector and Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Viral Vector and Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Adenovirus
Figure 12. Product Picture of Fowlpox Virus
Figure 13. Product Picture of Attenuated Yellow Fever
Figure 14. Product Picture of Vaccinia Virus Vectors
Figure 15. Global Viral Vector and Vaccine Sales Market Share by Type in 2026
Figure 16. Global Viral Vector and Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Viral Vector and Vaccine Consumed in Research Institutes
Figure 18. Global Viral Vector and Vaccine Market: Research Institutes (2021-2026) & (K Units)
Figure 19. Viral Vector and Vaccine Consumed in Biopharmaceutical Companies
Figure 20. Global Viral Vector and Vaccine Market: Biopharmaceutical Companies (2021-2026) & (K Units)
Figure 21. Viral Vector and Vaccine Consumed in Others
Figure 22. Global Viral Vector and Vaccine Market: Others (2021-2026) & (K Units)
Figure 23. Global Viral Vector and Vaccine Sale Market Share by Application (2025)
Figure 24. Global Viral Vector and Vaccine Revenue Market Share by Application in 2026
Figure 25. Viral Vector and Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global Viral Vector and Vaccine Sales Market Share by Company in 2026
Figure 27. Viral Vector and Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global Viral Vector and Vaccine Revenue Market Share by Company in 2026
Figure 29. Global Viral Vector and Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Viral Vector and Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Viral Vector and Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Viral Vector and Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas Viral Vector and Vaccine Sales Market Share by Country in 2026
Figure 40. Americas Viral Vector and Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Viral Vector and Vaccine Sales Market Share by Region in 2026
Figure 48. APAC Viral Vector and Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Viral Vector and Vaccine Sales Market Share by Country in 2026
Figure 59. Europe Viral Vector and Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Viral Vector and Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Viral Vector and Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Viral Vector and Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Viral Vector and Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Viral Vector and Vaccine in 2026
Figure 76. Manufacturing Process Analysis of Viral Vector and Vaccine
Figure 77. Industry Chain Structure of Viral Vector and Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Viral Vector and Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global Viral Vector and Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Viral Vector and Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Viral Vector and Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Viral Vector and Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Viral Vector and Vaccine Revenue Market Share Forecast by Application (2027-2032)
